Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr Kamdar on Optimizing Patient Monitoring After Liso-Cel in MCL

July 29th 2025

Manali Kamdar, MD, discusses the rationale for optimizing monitoring after the treatment of liso-cel in patients with mantle cell lymphoma.

Sonrotoclax Plus Zanubrutinib Generates Durable Responses in R/R Mantle Cell Lymphoma

July 25th 2025

The combination of sonrotoclax and zanubrutinib produced deep and durable responses in relapsed/refractory mantle cell lymphoma.

FDA Approves Generic Ibrutinib Tablets for B-Cell Malignancies

July 24th 2025

The FDA has approved a generic version of ibrutinib tablets for B-cell malignancies.

European Commission Approves Ibrutinib in Treatment-Naive, Transplant-Eligible MCL

July 23rd 2025

Ibrutinib has received an expanded indication from the European Commission for the treatment of patients with newly diagnosed MCL eligible for transplant.

Long-Term Data Suggest Potential Functional Cure With MCL2/MCL3 Regimen in Younger Patients With Mantle Cell Lymphoma

July 20th 2025

Mats Jerkeman, MD, discusses long-term follow-up data of the Nordic MCL2 and MCL3 trials in younger patients with mantle cell lymphoma.

Dr Kamdar on Patient Monitoring After Liso-Cel in MCL and Hematologic Malignancies

July 14th 2025

Manali Kamdar, MD, discusses an analysis of the timing of CRS and ICANS among patients with MCL and other hematologic malignancies treated with liso-cel.

Glofitamab Plus Pirtobrutinib Yields High Activity, Tolerability in Covalent BTK Inhibitor–Exposed MCL

July 11th 2025

Results from the GoldiLox trial showed high complete and MRD-negative responses with glofitamab plus pirtobrutinib in covalent BTK inhibitor–exposed MCL.

Dr Arora on A Retrospective Analysis of Temporal Trends to Assess MCL Incidence From 2000-2021

July 9th 2025

Ruby Arora, MD, discusses the design of a retrospective analysis of temporal trends in MCL incidence from 2000 to 2021.

Dr Arora on Findings From a SEER Database Analysis in Mantle Cell Lymphoma

June 30th 2025

Ruby Arora, MD, discusses findings from a SEER database analysis of mantle cell lymphoma incidence rates from 2000 to 2021.

FDA Removes REMS Programs for All Currently Approved CD19- and BCMA-Directed CAR T-Cell Therapies in Hematologic Malignancies

June 30th 2025

The FDA has eliminated REMS programs for BCMA- and CD19-directed autologous CAR T-cell therapies approved for multiple myeloma and select types of lymphoma/leukemia.

Dr Danilov on the Evolution of Chemotherapy-Free Treatment Options in MCL

June 27th 2025

Alexey Danilov, MD, PhD, discussed how chemotherapy-free regimens have influenced treatment decision-making for patients with mantle cell lymphoma.

Dr Kahl on the Evolving Role of BTK Inhibitors in MCL

June 27th 2025

Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the mantle cell lymphoma treatment paradigm.

FDA Approves Changes to Monitoring Requirements, Removal of REMS Programs for Liso-Cel and Ide-Cel in B-Cell Malignancies

June 27th 2025

The FDA updated the labels for liso-cel and ide-cel to reduce monitoring select requirements and remove REMS programs for the CAR T-cell therapies.

Novel Targeted, Chemo-Free, and Cellular Therapies Are Poised to Transform Treatment Paradigms in B-Cell Malignancies

June 25th 2025

Alexey Danilov, MD, PhD, shares key developments and areas of debate from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

ZR2 Plus R-DHAP and Zanubrutinib Maintenance With/Without ASCT Displays Promising Efficacy in Newly Diagnosed MCL

June 24th 2025

R2 followed by R-DHAP led to an ORR of 93.3% in patients with newly diagnosed MCL.

MRD Negativity Is Prognostic for Survival and Maintained With Frontline Acalabrutinib/BR in MCL

June 24th 2025

Acalabrutinib plus BR prolonged duration of MRD negativity vs BR alone in previously untreated MCL, supporting the use of MRD as a prognostic biomarker.

First-Line Ibrutinib Plus Venetoclax Demonstrates Activity in Older Patients With MCL

June 23rd 2025

Ibrutinib plus venetoclax led to complete responses and durable remissions in the first-line treatment of older patients with MCL.

CHMP Recommends Ibrutinib Plus Chemoimmunotherapy for Frontline, Transplant-Eligible Mantle Cell Lymphoma

June 20th 2025

CHMP recommended ibrutinib plus immunochemotherapy for previously untreated, transplant-eligible mantle cell lymphoma.

Ibrutinib Plus Venetoclax and A CD20 Monoclonal Antibody Increases MRD Negativity in Untreated MCL

June 17th 2025

Treatment with ibrutinib plus venetoclax and a CD20 monoclonal antibody induced high MRD negativity rates vs ibrutinib/anti-CD20 in untreated MCL.

FDA Approves Tablet Formulation of Zanubrutinib for B-Cell Malignancies

June 11th 2025

The FDA has approved a tablet formulation of zanubrutinib for use in all 5 approved indications of the capsule formulation.